Progress Takes Many Forms When It Comes to Fighting Chronic Conditions Like Alzheimer’s Disease

April 17, 2026 (Washington, D.C.) The Partnership to Fight Chronic Disease (PFCD) released the following statement today in response to recent analyses related to Alzheimer’s disease.

“The recent review of anti-amyloid Alzheimer’s therapies highlights the complexity of measuring progress against a devastating disease, but its conclusions should be viewed with important context. By combining older, unsuccessful therapies with newer treatments that have demonstrated the ability to slow cognitive decline, the analysis risks misrepresenting meaningful advances and diminishing what these medicines can offer patients and families today.

“For those living with Alzheimer’s and related dementias, even modest slowing of disease progression, such as the reductions in decline observed in recent trials, can translate into more time with loved ones, greater independence, and a critical window for future breakthroughs. Dismissing these gains because they are not cures overlooks what matters most to patients and caregivers.

“At a time when the burden of Alzheimer’s continues to grow, the answer is not to step back

from innovation, but to build on it, advancing a range of scientific approaches, improving how we measure meaningful outcomes, and ensuring patients have access to emerging therapies. The Partnership to Fight Chronic Disease remains committed to supporting continued research, thoughtful evaluation of evidence, and policies that accelerate progress for the millions of Americans affected by this disease.”

###